Oncology Medical News about Glioblastoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Recurrent glioblastoma of childhood treated with bevacizumab: case report and molecular features
Child's Nervous System, 10/29/09

Zhang W et al. – Childhood glioblastomas show a distinct biological behavior and probably a different molecular pathogenesis in comparison to the adult ones. Understanding the molecular mechanisms responsible for the formation and progression of the tumors is critical for identification of novel therapeutic targets.

Exclusive Author Commentary
Tao Jiang, 10/30/09

Childhood glioblastoma multiforme is an uncommon brain tumor. Bevacizumab is a novel antiangiogenic agent, which has been reported recently in recurrent GBM. In this paper, we report a case of childhood GBM treated with bevacizumab and investigate the molecular alterations before and after recurrence. This study has determined, for the first time, the correlations of molecular features with clinical outcomes of childhood GBM treated with bevacizumab. Our findings may also have general implications in the cell biology of gliomas. We strongly believe the contribution of this study warrants its publication in Child's Nervous System.

<< Previous
Genetic variants in GSTM3 gene within...

Next >>
In pursuit of prognostic factors in children with pilocytic...